Revolution Medicines to Participate in Upcoming Investor Conferences

Rhea-AI Impact
Rhea-AI Sentiment

REDWOOD CITY, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the Goldman Sachs 44th Annual Global Healthcare Conference and in Barclays’ ongoing series of virtual lunchtime fireside chats.

Details of the company’s participation are as follows:

  • Goldman Sachs 44th Annual Global Healthcare Conference
    Conference Dates: June 12-15, 2023
    Fireside Chat Time/Date: 11:40 a.m. Eastern on Wednesday, June 14, 2023
    Location: Dana Point, California; webcast available
  • Barclays Virtual Fireside Chat Series
    Fireside Chat Time/Date: 12:00 p.m. Eastern on Thursday, June 15, 2023
    Location: Virtual; webcast available

To access the live webcasts of the Goldman Sachs and Barclays fireside chats, please visit the “Events & Presentations” page of Revolution Medicines’ website at Additionally, a replay of each webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RASMULTI) and RMC-6291(KRASG12C) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805 (KRASG12D) and RMC-0708 (KRASQ61H), both of which are currently in IND-enabling development, RMC-8839 (KRASG13C), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

Revolution Medicines Inc


RVMD Rankings

RVMD Latest News

RVMD Stock Data

Biological Product (except Diagnostic) Manufacturing
Health Technology, Pharmaceuticals: Other, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Redwood City

About RVMD

revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.